FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A

SAN RAFAEL, Calif., Oct. 26, 2017 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formerly BMN 270) Breakthrough ... Biopharmaceuticals, FDA BioMarin Pharmaceutical, Valoctocogene, Roxaparvovec, Hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news